» Articles » PMID: 38542836

The Roles of Exosome-Derived MicroRNAs in Cardiac Fibrosis

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2024 Mar 28
PMID 38542836
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular disease (CVD) stands as the foremost cause of patient mortality, and the lack of early diagnosis and defined treatment targets significantly contributes to the suboptimal prevention and management of CVD. Myocardial fibrosis (MF) is not only a complex pathogenic process with no effective treatment currently available but also exerts detrimental effects on the progression of various cardiovascular diseases, thereby escalating their mortality rates. Exosomes are nanoscale biocommunication vehicles that facilitate intercellular communication by transporting bioactive substances, such as nucleic acids and proteins, from specific cell types. Numerous studies have firmly established that microRNAs (miRNAs), as non-coding RNAs, wield post-transcriptional regulatory mechanisms and exhibit close associations with various CVDs, including coronary heart disease (CHD), atrial fibrillation (AF), and heart failure (HF). MiRNAs hold significant promise in the diagnosis and treatment of cardiovascular diseases. In this review, we provide a concise introduction to the biological attributes of exosomes and exosomal miRNAs. We also explore the roles and mechanisms of distinct cell-derived exosomal miRNAs in the context of myocardial fibrosis. These findings underscore the pivotal role of exosomes in the diagnosis and treatment of cardiac fibrosis and emphasize their potential as biotherapies and drug delivery vectors for cardiac fibrosis treatment.

Citing Articles

The immune regulatory role of exosomal miRNAs and their clinical application potential in heart failure.

Guo D, Yan J, Yang Z, Chen M, Zhong W, Yuan X Front Immunol. 2024; 15:1476865.

PMID: 39687609 PMC: 11647038. DOI: 10.3389/fimmu.2024.1476865.


Transforming Cardiotoxicity Detection in Cancer Therapies: The Promise of MicroRNAs as Precision Biomarkers.

Moscoso I, Rodriguez-Manero M, Cebro-Marquez M, Vilar-Sanchez M, Serrano-Cruz V, Vidal-Abeijon I Int J Mol Sci. 2024; 25(22).

PMID: 39595980 PMC: 11593668. DOI: 10.3390/ijms252211910.


Exosomes Induce Crosstalk Between Multiple Types of Cells and Cardiac Fibroblasts: Therapeutic Potential for Remodeling After Myocardial Infarction.

Feng Y, Wang Y, Li L, Yang Y, Tan X, Chen T Int J Nanomedicine. 2024; 19:10605-10621.

PMID: 39445157 PMC: 11498042. DOI: 10.2147/IJN.S476995.

References
1.
Lalit P, Salick M, Nelson D, Squirrell J, Shafer C, Patel N . Lineage Reprogramming of Fibroblasts into Proliferative Induced Cardiac Progenitor Cells by Defined Factors. Cell Stem Cell. 2016; 18(3):354-67. PMC: 4779406. DOI: 10.1016/j.stem.2015.12.001. View

2.
Kanemitsu H, Takai S, Tsuneyoshi H, Nishina T, Yoshikawa K, Miyazaki M . Chymase inhibition prevents cardiac fibrosis and dysfunction after myocardial infarction in rats. Hypertens Res. 2006; 29(1):57-64. DOI: 10.1291/hypres.29.57. View

3.
Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C . CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014; 129(21):2111-24. DOI: 10.1161/CIRCULATIONAHA.113.007101. View

4.
Scherer P . The many secret lives of adipocytes: implications for diabetes. Diabetologia. 2018; 62(2):223-232. PMC: 6324990. DOI: 10.1007/s00125-018-4777-x. View

5.
Phinney D, Di Giuseppe M, Njah J, Sala E, Shiva S, St Croix C . Mesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs. Nat Commun. 2015; 6:8472. PMC: 4598952. DOI: 10.1038/ncomms9472. View